Higher Doses of First-Line TB Drugs Linked to Increased Adverse Events Rates in Pediatric Patients

30 May 2025

Pediatric patients who received higher doses of first-line TB drugs based on 2010 recommendations from the World Health Organization exhibited increased risk for adverse events and drug-related adverse events (AEs).

Researchers conducted a systematic review and meta-analysis to compare the rate of AEs associated with first-line TB treatment among children and adolescents before vs after the WHO recommended higher doses (pre- vs post-WHO 2010 dosing) for pediatric populations. All study patients had presumed drug-susceptible TB disease. The researchers also evaluated drug-related AEs and AE severity between dosing groups.

Read the full news story at Infectious Disease Advisor.